CA2976383C - Iloperidone for the treatment of schizophrenia - Google Patents
Iloperidone for the treatment of schizophrenia Download PDFInfo
- Publication number
- CA2976383C CA2976383C CA2976383A CA2976383A CA2976383C CA 2976383 C CA2976383 C CA 2976383C CA 2976383 A CA2976383 A CA 2976383A CA 2976383 A CA2976383 A CA 2976383A CA 2976383 C CA2976383 C CA 2976383C
- Authority
- CA
- Canada
- Prior art keywords
- iloperidone
- daily dose
- acceptable salt
- patients
- maintenance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562117173P | 2015-02-17 | 2015-02-17 | |
| US62/117,173 | 2015-02-17 | ||
| US201562172436P | 2015-06-08 | 2015-06-08 | |
| US62/172,436 | 2015-06-08 | ||
| PCT/US2016/018316 WO2016134049A1 (en) | 2015-02-17 | 2016-02-17 | Iloperidone for the treatment of schizophrenia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2976383A1 CA2976383A1 (en) | 2016-08-25 |
| CA2976383C true CA2976383C (en) | 2023-05-23 |
Family
ID=55532275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2976383A Active CA2976383C (en) | 2015-02-17 | 2016-02-17 | Iloperidone for the treatment of schizophrenia |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10441580B2 (enExample) |
| EP (1) | EP3258935B1 (enExample) |
| JP (1) | JP6885649B2 (enExample) |
| KR (1) | KR102870956B1 (enExample) |
| CN (2) | CN116211857A (enExample) |
| BR (1) | BR112017017608A2 (enExample) |
| CA (1) | CA2976383C (enExample) |
| ES (1) | ES2870498T3 (enExample) |
| WO (1) | WO2016134049A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11214827B2 (en) | 2018-08-30 | 2022-01-04 | Vanda Pharmaceuticals Inc. | Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone |
| IL321015A (en) * | 2022-12-19 | 2025-07-01 | Vanda Pharmaceuticals Inc | ILOPERIDONE dosing regimen for the treatment of bipolar I disorder and schizophrenia |
| AU2024278999A1 (en) | 2023-06-02 | 2025-11-13 | Vanda Pharmaceuticals Inc. | Method of treatment with iloperidone |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2370634T3 (es) | 2001-08-31 | 2011-12-21 | Novartis Ag | Isómeros ópticos de un metabolito de iloperidona. |
| WO2003037337A1 (en) | 2001-10-30 | 2003-05-08 | Novartis Ag | Depot formulations of iloperidone and a star polymer |
| GB0216416D0 (en) | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
| US20100063093A1 (en) * | 2007-03-28 | 2010-03-11 | Curt Wolfgang | Methods for the administration of iloperidone |
| CA3113166A1 (en) * | 2004-09-30 | 2006-04-13 | Vanda Pharmaceuticals Inc. | Methods for the administration of iloperidone |
| WO2009036056A1 (en) | 2007-09-10 | 2009-03-19 | Vanda Pharmaceuticals, Inc. | Antipsychotic treatment based on snp genotype |
| HUE053904T2 (hu) | 2007-12-19 | 2021-07-28 | Janssen Pharmaceutica Nv | Hosszan tartó hatású injektálható paliperidon-észterekkel kapcsolatos adagolási rendek |
| ES2533091T3 (es) * | 2009-05-15 | 2015-04-07 | Vanda Pharmaceuticals Inc. | Tratamiento antipsicótico basado en genotipo de SNP de DRD2 o ANKK1 |
| US20140350029A1 (en) | 2011-12-02 | 2014-11-27 | Dainippon Sumitomo Pharma Co., Ltd. | Lurasidone novel dosage regimens and use thereof for the treatment, prevention, and/or management of at least one cns disorder |
| CN108938632A (zh) | 2012-03-14 | 2018-12-07 | 万达制药公司 | 用于治疗精神疾病的伊潘立酮代谢物及其应用 |
| IL275725B (en) * | 2012-08-21 | 2022-08-01 | Sage Therapeutics Inc | Treatment methods for epilepsy and status epilepticus |
-
2016
- 2016-02-17 JP JP2017543816A patent/JP6885649B2/ja active Active
- 2016-02-17 CN CN202310398029.9A patent/CN116211857A/zh active Pending
- 2016-02-17 CN CN201680010479.4A patent/CN107249586A/zh active Pending
- 2016-02-17 WO PCT/US2016/018316 patent/WO2016134049A1/en not_active Ceased
- 2016-02-17 ES ES16710038T patent/ES2870498T3/es active Active
- 2016-02-17 BR BR112017017608-4A patent/BR112017017608A2/en not_active Application Discontinuation
- 2016-02-17 US US15/549,820 patent/US10441580B2/en active Active
- 2016-02-17 EP EP16710038.7A patent/EP3258935B1/en active Active
- 2016-02-17 CA CA2976383A patent/CA2976383C/en active Active
- 2016-02-17 KR KR1020177026225A patent/KR102870956B1/ko active Active
-
2019
- 2019-09-06 US US16/562,548 patent/US10987346B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10987346B2 (en) | 2021-04-27 |
| EP3258935B1 (en) | 2021-04-07 |
| EP3258935A1 (en) | 2017-12-27 |
| US10441580B2 (en) | 2019-10-15 |
| HK1248551A1 (zh) | 2018-10-19 |
| CN116211857A (zh) | 2023-06-06 |
| KR20170118830A (ko) | 2017-10-25 |
| BR112017017608A2 (en) | 2018-05-08 |
| JP6885649B2 (ja) | 2021-06-16 |
| JP2018505901A (ja) | 2018-03-01 |
| ES2870498T3 (es) | 2021-10-27 |
| CA2976383A1 (en) | 2016-08-25 |
| KR102870956B1 (ko) | 2025-10-16 |
| US20190388412A1 (en) | 2019-12-26 |
| WO2016134049A1 (en) | 2016-08-25 |
| US20180021324A1 (en) | 2018-01-25 |
| CN107249586A (zh) | 2017-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zajecka et al. | A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder | |
| Hermann et al. | First use of cenerimod, a selective S1P1 receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study | |
| US10987346B2 (en) | Iloperidone for the treatment of schizophrenia | |
| CA3075719A1 (en) | Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults | |
| Shiovitz et al. | A randomized, double-blind, placebo-controlled trial of the efficacy and safety of levomilnacipran ER 40-120mg/day for prevention of relapse in patients with major depressive disorder | |
| JP2024050575A (ja) | Ｌ－４－クロロキヌレニンの治療的使用 | |
| Allgulander et al. | A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder | |
| KR20240060820A (ko) | 혈전색전성 장애의 예방 및 치료를 위한 밀벡시안 | |
| JP2017128610A (ja) | 併用ａｌｓ療法 | |
| Singh et al. | Relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants | |
| Burt et al. | Duloxetine for the treatment of major depressive disorder in women ages 40 to 55 years | |
| Bennett et al. | The role of ondansetron in the treatment of schizophrenia | |
| KR102642795B1 (ko) | 망막 질환을 치료하기 위한 미라베그론 | |
| HK1248551B (en) | Iloperidone for the treatment of schizophrenia | |
| Doyle et al. | Psychotropic medications, associated QTc prolongation, and sudden cardiac death: a review for clinicians | |
| JP2017528517A (ja) | 多汗症を治療するための方法 | |
| Farmer et al. | Pharmacological intervention for disruptive behaviors in intellectual and developmental disabilities: the glass is half full | |
| Qiu et al. | Metformin alleviates ribociclib-induced lung injury by restoring impaired autophagy via targeting Mucolipin-1 | |
| Placebo-Controlled | Long-Term Remission With Cariprazine Treatment in Patients With Schizophrenia | |
| Takekita et al. | P. 3. c. 024 Comparison of perospirone and aripiprazole: a 12 weeks, randomised, open-label study in Japanese schizophrenia patients | |
| JP2018507216A (ja) | 多発性骨髄腫に対するパノビノスタット投与量 | |
| WO2021255438A1 (en) | Combination of dexamethasone and a mineralocorticoid receptor antagonist for use in the treatment of acute respiratory distress syndrome | |
| Rajiv et al. | First-line Therapy in Status Epilepticus | |
| CN108938645A (zh) | 一种抗精神病药物组合物 | |
| Correll et al. | The Effects of Valbenazine in Participants with Tardive Dyskinesia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20201016 |
|
| EEER | Examination request |
Effective date: 20201016 |
|
| EEER | Examination request |
Effective date: 20201016 |
|
| EEER | Examination request |
Effective date: 20201016 |
|
| EEER | Examination request |
Effective date: 20201016 |
|
| EEER | Examination request |
Effective date: 20201016 |
|
| EEER | Examination request |
Effective date: 20201016 |